486460-20-2

Basic information

• Product Name: 3-(Trifluoromethyl)-1,2,4-triazolo[4,3-a]pyrazine
• Synonyms: 3-(TRIFLUOROMETHYL)-1,2,4-TRIAZOLO[4,3-A]-PYRAZINE;3-(TRIFLUOROMETHYL)-[1,2,4]TRIAZOLO[4,3-A]PYRAZINE,95% MIN(HPLC)
• CAS NO: 486460-20-2
• Molecular Formula: C₆H₃F₃N₄
• Molecular Weight: 188.11
• Mol File: 486460-20-2.mol
• Article Data: 12

Chemical Properties

• Appearance: /
• Density: 1.69 g/cm³
• Refractive Index: 1.606
• Storage Temp.: 2-8°C
• PKA: -2.40±0.30(Predicted)
• CAS DataBase Reference: 3-(Trifluoromethyl)-1,2,4-triazolo[4,3-a]pyrazine(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(Trifluoromethyl)-1,2,4-triazolo[4,3-a]pyrazine(486460-20-2)
• EPA Substance Registry System: 3-(Trifluoromethyl)-1,2,4-triazolo[4,3-a]pyrazine(486460-20-2)

Safety Data

• Hazardous Substances Data: 486460-20-2(Hazardous Substances Data)

Usage

Uses

3-(Trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyrazine can be used as reactant/reagent in synthetic preparation of 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for treatment or prevention of diabetes.

InChI:InChI=1/C6H3F3N4/c7-6(8,9)5-12-11-4-3-10-1-2-13(4)5/h1-3H

Upstream product

• 54608-52-5 2-hydrazinylpyrazine 
• 76-05-1 trifluoroacetic acid 
• 407-25-0 trifluoroacetic anhydride 
• 1447800-65-8 2-(1-bromo-2,2,2-trifluoroethylidene)-1-(pyrazin-2-yl)hydrazine 
• 1447800-62-5 2-(2,2,2-trifluoroethylidene)-1-(pyrazin-2-yl)hydrazine 

Downstream Products

• 1438071-81-8 N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-(3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo [4,3-a]pyrazin-7(8H)-yl)propoxy)quinazolin-4-amine 
• 762240-92-6 3-(trifluoromethyl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazine hydrochloride 
• 486459-71-6 Sitagliptin hydrochloride 
• 486460-23-5 (R)-tert-butyl 4-oxo-4-(3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)-1-(2,4,5-trifluorophenyl)butan-2-ylcarbamate 
• 486460-22-4 7-[(3R)-3-[(1,1-dimethylethoxycarbonyl)amino]-4-(2,5-difluorophenyl)butanoyl]-3-(trifluoromethyl)-5,6,7,8-tetrahydro-1,2,4-triazolo[4,3-a]pyrazine 
• 1025835-55-5 [1-(3,4-difluoro-benzyl)-3-oxo-3-(3-trifluoromethyl-5,6-dihydro-8H-[1,2,4]triazolo[4,3-a]pyrazin-7-yl)-propyl]-carbamic acid tert-butyl ester 
• 486460-32-6 sitagliptin 
• 486460-31-5 7-[(3R)-3-amino-4-(2,5-difluorophenyl)butanoyl]-3-(trifluoromethyl)-5,6,7,8-tetrahydro-1,2,4-triazolo[4,3-a]pyrazine 
• 486460-21-3 3-trifluoromethyl-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazine 

Relevant articles and documents

Microwave-Assisted Synthesis and Antituberculosis Screening of Some 4-((3-(Trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-l)methyl)benzenamine Hybrids

In the present investigation, a series of 4-((3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)methyl)benzenamine analogs 6a–o were synthesized and characterized by IR, NMR (1H and 13C), and mass spectra. All newly synthesized compounds 6a–o were prepared under conventional and microwave irradiation methods. These compounds obtained in higher yields and in shorter reaction times in the microwave irradiation method when compared with the conventional method. Synthesized compounds 6a–o were inspected for their in vitro antitubercular activity against Mycobacterium tuberculosis H37Ra using an established XTT reduction menadione assay. Among the screened compounds, 6i (IC50: 1.82?μg/mL), 6j (IC50: 1.02?μg/mL), and 6k (IC50: 1.59?μg/mL) showed excellent activity. Furthermore, compound 6i showed MIC90 value of 16.02?μg/mL. In summary, the results indicate the identification of some novel, selective, and specific inhibitors against M.?tuberculosis that can be explored further for the potential antitubercular drug.

Methods for Treating Cognitive Disorders Using Inhibitors of Histone Deacetylase

This disclosure relates to compounds for the inhibition of histone deacetylase and treatment of a cognitive disorder or deficit. More particularly, the disclosure provides for compounds of formula (I) wherein Q, J, L and Z are as defined in the specification.

BETA-AMINO HETEROCYCLIC DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES

The present invention is directed to compounds which are inhibitors of the dipeptidyl peptidase-IV enzyme (“DP-IV inhibitors”) and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.